secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2026-04-29T23:59:59+00:00
Accession:  0001171843-26-002796
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva Q1 revenues $4.0B (+2% YoY); AUSTEDO up 41%; to acquire Emalex for $700M cash
--------------------------------------------------------------------------------

- Q1 GAAP diluted EPS $0.31; Non-GAAP diluted EPS $0.53; revenues $3,982M (+2% USD, -3% LC).
- Key innovative brands: AUSTEDO $578M (+41% YoY), AJOVY $196M (+35%), UZEDY $63M (+62%).
- Generics down 16% LC due to lenalidomide competition and Japan BV divestiture.
- Acquired Emalex Biosciences for $700M upfront + up to $200M milestones + royalties; ecopipam (Tourette) NDA-ready; close expected Q3 2026.
- 2026 outlook maintained; Non-GAAP diluted EPS $1.91-$2.11 (stand-alone $2.57-$2.77).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000117184326002796/0001171843-26-002796-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000117184326002796/f8k_042926.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-002796

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer